In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers - PubMed (original) (raw)
Comparative Study
In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers
B J Monk et al. Gynecol Oncol. 1998 Nov.
Abstract
Objective: To compare the in vitro cytotoxicity of nedaplatin, an investigational platinum analog, with that of cisplatin and carboplatin against fresh cervical cancers from untreated patients.
Methods: Specimens were obtained prior to irradiation or radical surgery from 20 patients with locally invasive cervical carcinoma. Cytotoxicity was measured after single cell suspensions were grown in agar using colony counts and incorporation of [3H]thymidine. Nedaplatin and cisplatin were tested at 1 and 10 micrograms/ml dose levels while carboplatin was tested at 10 and 100 micrograms/ml dose levels continuously. When single hour exposures were used, drug doses were increased by 10-fold.
Results: The median drug concentrations associated with a 50% inhibition of growth (IC50) for nedaplatin, cisplatin, and carboplatin were 0.435, 0.73, and 18.6 micrograms/ml, respectively. At 10 micrograms/ml for both cisplatin and nedaplatin and 100 micrograms/ml for carboplatin, cisplatin was the most active drug with 70% of tumors sensitive (</=50% survival relative to control plates) to cisplatin and 45 and 50% sensitive to nedaplatin and carboplatin, respectively (P = 0.015, P = 0.074). Six of 20 (30%) tumors resistant to cisplatin were also resistant to nedaplatin and carboplatin.
Conclusion: At doses approximating clinically achievable drug concentrations as defined by the mean plasma concentration time product, cisplatin appears more cytotoxic in vitro than either carboplatin or nedaplatin among chemotherapy-naive cervical cancers. However, nedaplatin and carboplatin are also active agents with similar activity. Since differences in drug sensitivity may be related to subtle differences in dose and schedule and the pharmacokinetics and safety profile of nedaplatin are favorable, clinical trials of nedaplatin are indicated.
Copyright 1998 Academic Press.
Similar articles
- In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers.
Alberts DS, Fanta PT, Running KL, Adair LP Jr, Garcia DJ, Liu-Stevens R, Salmon SE. Alberts DS, et al. Cancer Chemother Pharmacol. 1997;39(6):493-7. doi: 10.1007/s002800050604. Cancer Chemother Pharmacol. 1997. PMID: 9118460 - Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA, Harrap KR. Kelland LR, et al. Cancer Res. 1993 Jun 1;53(11):2581-6. Cancer Res. 1993. PMID: 8388318 - Chemosensitivity testing of a novel platinum analog, nedaplatin (254-S), in human gynecological carcinomas: a comparison with cisplatin.
Koshiyama M, Kinezaki M, Uchida T, Sumitomo M. Koshiyama M, et al. Anticancer Res. 2005 Nov-Dec;25(6C):4499-502. Anticancer Res. 2005. PMID: 16334133 - Platinum compounds in cervical and endometrial cancers: focus on carboplatin.
Muggia FM, Muderspach L. Muggia FM, et al. Semin Oncol. 1994 Apr;21(2 Suppl 2):35-41; quiz 42, 58. Semin Oncol. 1994. PMID: 8202719 Review. - Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance.
Kelland LR, Sharp SY, O'Neill CF, Raynaud FI, Beale PJ, Judson IR. Kelland LR, et al. J Inorg Biochem. 1999 Oct;77(1-2):111-5. J Inorg Biochem. 1999. PMID: 10626362 Review.
Cited by
- Paclitaxel plus nedaplatin vs. paclitaxel plus carboplatin in women with epithelial ovarian cancer: A multi-center, randomized, open-label, phase III trial.
Li L, Zhuang Q, Cao Z, Yin R, Zhu Y, Zhu L, Xie X, Zhang Y, Li L, Wu Q, Zheng J, Zhou Q, Li X, Wu L, Feng Y, Wang C. Li L, et al. Oncol Lett. 2018 Mar;15(3):3646-3652. doi: 10.3892/ol.2018.7761. Epub 2018 Jan 10. Oncol Lett. 2018. PMID: 29467885 Free PMC article. - Efficacy and safety of DoceAqualip in a patient with locally advanced cervical cancer: A case report.
Prasanna R, Bunger D, Khan MA. Prasanna R, et al. Mol Clin Oncol. 2018 Feb;8(2):296-299. doi: 10.3892/mco.2017.1519. Epub 2017 Nov 27. Mol Clin Oncol. 2018. PMID: 29435291 Free PMC article. - Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.
Fujiwara M, Isohashi F, Mabuchi S, Yoshioka Y, Seo Y, Suzuki O, Sumida I, Hayashi K, Kimura T, Ogawa K. Fujiwara M, et al. J Radiat Res. 2015 Mar;56(2):305-14. doi: 10.1093/jrr/rru101. Epub 2014 Nov 26. J Radiat Res. 2015. PMID: 25428244 Free PMC article. - A phase II study of concurrent chemo-radiotherapy with weekly nedaplatin in advanced squamous cell carcinoma of the uterine cervix.
Yuan G, Wu L, Huang M, Li N, An J. Yuan G, et al. Radiat Oncol. 2014 Feb 18;9:55. doi: 10.1186/1748-717X-9-55. Radiat Oncol. 2014. PMID: 24533532 Free PMC article. Clinical Trial. - Nedaplatin: a cisplatin derivative in cancer chemotherapy.
Shimada M, Itamochi H, Kigawa J. Shimada M, et al. Cancer Manag Res. 2013 May 8;5:67-76. doi: 10.2147/CMAR.S35785. Print 2013. Cancer Manag Res. 2013. PMID: 23696716 Free PMC article.